[Specific treatment of transthyretin amyloid cardiomyopathy: established disease-modifying agents and emerging mechanisms].
- DOI
- 10.23785/tu.2026.05.006
- Published
- 2026 Oct
- Container
- Therapeutische Umschau. Revue therapeutique
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.23785/tu.2026.05.006,
title = {[Specific treatment of transthyretin amyloid cardiomyopathy: established disease-modifying agents and emerging mechanisms].},
author = {Najaf Zadeh S and Hundertmark M},
year = {2026},
journal = {Therapeutische Umschau. Revue therapeutique},
doi = {10.23785/tu.2026.05.006},
url = {https://doi.org/10.23785/tu.2026.05.006}
}RIS
TY - JOUR TI - [Specific treatment of transthyretin amyloid cardiomyopathy: established disease-modifying agents and emerging mechanisms]. AU - Najaf Zadeh S AU - Hundertmark M PY - 2026 JO - Therapeutische Umschau. Revue therapeutique DO - 10.23785/tu.2026.05.006 UR - https://doi.org/10.23785/tu.2026.05.006 ER -
APA
S, N. Z., & M, H. (2026). [Specific treatment of transthyretin amyloid cardiomyopathy: established disease-modifying agents and emerging mechanisms].. Therapeutische Umschau. Revue therapeutique. https://doi.org/10.23785/tu.2026.05.006
Source records
- pubmed · retrieved 2026-11-10T15:50:39.820Z